Kornimate/medical-research-clean huggingface dataset:
plasma ropivacaine concentrations after sciatic nerve block in patients with chronic kidney disease

Conditions: Regional Anesthesia Morbidity; Local Anesthetic Drug Adverse Reaction

Summary: this prospective observational study aimed to examine the pharmacokinetics of ropivacaine in patients with chronic kidney disease after sciatic nerve block. sciatic nerve block for foot and ankle surgery will be performed using ropivacaine under ultrasound-guidance, and arterial blood test will be taken for total plasma ropivacaine concentration at 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block.


Eligibility criteria:
inclusion criteria: * patients scheduled for foot and ankle surgery * patients with chronic kidney disease (glomerular filtration rate \< 60 ml/min/1.73m2) (changed from 30 ml/min/1.73m2 to facilitate patient recruitment) * patients who are thought to be clinically helpful to receive sciatic nerve block rather than general anesthesia because of comorbidities such as cardiopulmonary dysfunction and cerebral dysfunction exclusion criteria: * patients who need to renal replacement therapy, such as hemodialysis * patients with liver disease (aspartate transaminase or alanine transaminase \> 80 iu/l) * patients with allergic disease * patients with previous history of drug allery * patients with chronic pain persisting 3 months
study of moc31-pe in antigen positive carcinomas

Conditions: Carcinoma

Summary: immunotoxins (its), monoclonal antibodies conjugated to plant or bacterial toxins, have been extensively investigated for their possible use as anti-tumor agents although not in carcinoma patients with minimal residual disease. various its have been tested in early clinical trials and recent studies demonstrate anti-tumor activity of it treatment in patients with glioblastoma and different solid tumors. systemic treatment with immunotoxins directed against carefully selected epithelial cell surface molecules may have a potential for eradicating also dormant metastatic tumor cells, as their action is independent of cell proliferation. the effector moieties of the it used here, the pseudomonas exotoxin a (pe), inhibits protein synthesis in eukaryotic cells by catalytic inactivation (ribosylation) of elongation factor 2 in the ribosome complex.


Eligibility criteria:
inclusion criteria: * histologically confirm epithelial carcinoma, verified to be positive for the targeting antigen(ep-cam/epithelial glyco protein 2)according to the criteria given below. * tumor specimens verified to be positive for the targeting antibody,i.e.egp2 positive (moc31) by immunocytochemical or histochemical staining. * signed written informed consent * patients with no clinically symptomatic central nervous system (cns) involvement. * both gender, age 18 -75 years old. * life expectancy of at least 3 months * eastern cooperative oncology group (ecog) performance status 0-2 * adequate hematologic, renal and hepatic function defined as: neutrophils \> 1.5 x 10\^9/l;platelets \> 100 x 10\^9/l; creatinine \< 120 umol/l; total bilirubin within normal range. liver enzymes (alat and asat \<2.5 unl: alkaline phosphatase \< 1.5 unl and ygt \< 1.5 unl). * coagulation parameters (pt, ptt) within normal range. exclusion criteria: * no medical history of hepatitis b or c infection * patients must have no ecg abnormalities * patients must not be hiv positive * female premenopausal patients should not be pregnant (must have a negative pregnancy test prior to inclusion) and should not be lactating. * patients must use effective contraception if of reproductive potential. * prior chemotherapy and/or radiation should be completed for at least 4 weeks prior to study enrolment

Keywords: mdt and dlt
immunity and infections in the psychiatric population

Conditions: COVID; Psychiatric Disorders

Summary: the main objective of this multicenter cohort study is to determine the degree of covid19 infection immunization of a population of psychiatric patients. the secondary objective of this cohort follow-up is to: 1. clinically characterize covid patients who are positive for serological testing 2. assess the socio-demographic, clinical and psychotropic determinants of a covid diagnosis 3. immunologically characterize covid patients who are positive for serological testing 4. exploring the links between susceptibility to covid19 and erythrocytic blood groups

all patients accepting to participate will be included in participating psychiatry services and will have a covid serological test for inclusion with confirmation at j15 including immune-genetics data. a comparison of covid patients versus no covid patients will be based on a clinical examination (psychiatric, somatic) and blood samples collected at j0 and j15.

Eligibility criteria:
inclusion criteria: * adult patient * hospitalized in one of the participating psychiatric wards during the inclusion period * signed informed consent exclusion criteria: * inability to obtain the consent of the patient or legal representative, if applicable * patient under safeguard of justice

Keywords: covid infection psychiatric population
mr elastography for the herniated intervertebral disc

Conditions: Intervertebral Disc Herniation

Summary: low back pain is a major cause of disability, especially in the working-age population. a total of 149 million working days are lost every year as a consequence of back pain. intervertebral disc (ivd) degeneration is thought to play a major role in chronic back and neck pain. decades of bench-top research in tissue mechanics have shown clear relationships between changes in mechanical properties and abnormal changes ivd structure and composition. our overall hypothesis is that measurements of ivd mechanical properties can provide valuable information about its structure and composition for early diagnosis of degeneration, quantification of degeneration progress, and evaluation of treatment strategies. magnetic resonance elastography (mre) is an imaging method to quantify mechanical properties from soft tissues. the objectives of this study are to evaluating repeatability and collecting base line data from healthy individuals; and to apply mre to patients with disc herniation.


Eligibility criteria:
inclusion criteria: * healthy controls must be generally healthy individuals in the age range of 18-65. * patients, 18 to 65 years old, who have undergone or will undergo mri as part of the diagnosis of back pain and are diagnosed with one or more herniated discs in the lumbar spine (aka, disc rupture). exclusion criteria: * participants with a history of neurological injury or disease will be excluded. * participants with contraindications to mri scanning will be excluded (e.g., electric/mechanical implant, device such as a pacemaker). * participants who are claustrophobic will be excluded. * participants who are \>250 lbs will be excluded (due to weight and physical constraints of - the scanner, i.e., 55 cm bore). * those unable to consent, pregnant women, children, and prisoners will be excluded. * people under the age of 18 will be excluded as well. * individuals who do not understand english (written or spoken) will be excluded
an observational study to evaluate effectiveness and safety of upadacitinib in chinese adult participants with moderate to severely active ulcerative colitis (uc)

Conditions: Ulcerative Colitis

Summary: ulcerative colitis (uc) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. the hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus.. this study will assess how effective upadacitinib is in treating uc within a chinese population. upadacitinib is an approved drug for treating uc. approximately 80 adult participants, who have been prescribed upadacitinib for uc by their physician in accordance with local label, will be enrolled in china. upadacitinib will be administered in accordance with the terms of the local marketing authorization, and treatment of participants will be determined solely by the investigator. participants in the study will be followed for up to 1 year. there will be no additional burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic and only data which are routinely collected during a regular visit will be utilized for this study.


Eligibility criteria:
inclusion criteria: * chinese participants meet the diagnosis of moderately to severely active ulcerative colitis (uc) * participants prescribed upadacitinib at discretion of their treating physicians based on sufficient consideration of benefits/risks for patients per local label * participant must be an adult (≥ 18 years) * participant must provide written authorization to use personal and/or health data prior to the entry into the study exclusion criteria: * participant participating in any interventional trials * participant with any contraindication to upadacitinib as listed on the local china label * participant unwilling or unable to comply with the study requirements, including completion of patient reported outcome questionnaires
ef5 in finding oxygen in tumor cells of patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer

Conditions: Primary Peritoneal Cavity Cancer; Stage I Endometrial Carcinoma; Stage I Ovarian Epithelial Cancer; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage II Endometrial Carcinoma; Stage II Ovarian Epithelial Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Ovarian Epithelial Cancer; Stage IV Endometrial Carcinoma; Stage IV Ovarian Epithelial Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer

Summary: this phase ii trial is studying how well ef5 works in finding oxygen in tumor cells of patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer. diagnostic procedures using the drug ef5 to find oxygen in tumor cells may help in planning cancer treatment

primary objectives: i. correlate the level of ef5 binding with pre-treatment hemoglobin level and tumor grade and stage in patients undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer. secondary objectives: i. correlate pre-treatment tumor hypoxia (as measured by ef5 binding) with time to progression and time to recurrence in these patients. ii. correlate ef5 binding with cd-31 expression (tumor vasculature), ki-67 expression (cellular proliferation), and erythropoietin signaling in these patients. outline: patients receive ef5 iv over 1-2½ hours on day 1. approximately 1-2 days later, patients undergo tumor resection or biopsy. patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect ef5 binding levels. patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving ef5 to measure systemic ef5 binding levels. patients are followed at 30-45 days after administration of ef5 and then every 3-6 months thereafter.

Eligibility criteria:
inclusion criteria: * histologically confirmed\* diagnosis of 1 of the following: * cervical cancer * ovarian epithelial cancer * endometrial cancer * peritoneal cavity cancer * requires surgery or biopsy for diagnosis or as standard initial treatment for the tumor * performance status - ecog 0-2 * wbc ≥ 2,000/mm\^3 * platelet count ≥ 100,000/mm\^3 * bilirubin normal * creatinine normal * creatinine clearance ≥ 60 ml/min * no significant cardiac condition that would preclude study participation * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 1 month after study participation * weight ≤ 130 kg * no other significant medical condition that would preclude study participation * no scheduled chemotherapy for the tumor within the past 3 months * no scheduled radiotherapy to the tumor within the past 3 months * no other concurrent investigational agents
long-acting parasternal blocks for analgesia after cardiac surgery

Conditions: Coronary Artery Bypass Graft Surgery

Summary: this is a randomized, double-blind, controlled clinical trial is to evaluate the duration of efficacy of parasternal blocks with the use of local anesthetic adjuncts for analgesia after coronary artery bypass grafting surgery.

this study will randomize patients to either standard pain control protocols or parasternal blocks after coronary artery bypass grafting-only surgery. this study will specifically examine the effectiveness and duration of analgesia of parasternal blocks with local anesthetic adjuncts, dexamethasone 10mg and dexmedetomidine 50mcg, added to the local anesthetic mixture

Eligibility criteria:
inclusion criteria: * patients coming for elective and urgent coronary artery bypass (cabg)-only surgery. exclusion criteria: * patients with a history of regular opioid use. * patients with a history of chronic pain. * patients unable to provide consent.

Keywords: cardiac surgery pain
prayer as a possible adjuvant treatment for breast cancer

Conditions: Breast Neoplasms

Summary: the goal of this study is to help determine the biochemical mechanisms underlying previously demonstrated health benefits of prayer, and to track humoral changes in various prayer activities.

the purpose of this pilot study is to investigate certain biological mechanisms that may underlie the beneficial effects seen among cancer patients who pray. it will evaluate the effect of prayer on humoral (including biochemical/physiological inflammatory/immune) parameters, monitor changes in cancer related biomarkers and evaluate the effect of prayer on blood pressure, quality of life, health and dietary habits in relation to prayer activities, using validated questionnaires.

Eligibility criteria:
inclusion criteria: 1. primary histological diagnosis of stage i-iv breast cancer. 2. initial diagnosis of breast cancer within 5 year of study enrollment. 3. not currently receiving chemotherapy or radiation therapy. hormone therapy is allowed. 4. life expectancy of at least 12 months. 5. ecog performance status of 0, 1, or 2. 6. willing to sign informed consent indicating that they are aware of the investigational nature of the study and the randomized study design. 7. willing to comply with monthly follow-up phone calls. 8. willing to complete questionnaires at regular oncology clinic visits. 9. able to read write \& understand english. exclusion criteria: 1. concurrent treatment with chemotherapy or radiation therapy 2. less than 3 months since last dose of chemotherapy or radiation therapy. 3. breast cancer diagnosis more than 5 years prior to study enrollment 4. less than 21 or greater than to 80 years old. 5. life threatening or severe concurrent non-malignant conditions. 6. uncontrolled diabetes mellitus. 7. severe heart disease. 8. severe liver disease. severe lung disease. 9. history of smoking within 5 years of study enrollment. 10. psychological or psychiatric disorder that would interfere with study compliance. 11. history of missed appointments or poor medical compliance. 12. inability to understand instructions on how to complete a questionnaire. 13. no access to a phone.

Keywords: breast cancer stage one four
impact of optimized titration and delivery of bedtime insulin on prevention of nocturnal hypoglycemia

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to determine whether or not bedtime snacks are necessary to prevent overnight low blood glucose reactions (nocturnal hypoglycemia) in adults with type 1 diabetes who are using intensive insulin therapies, either multiple injections of insulin or insulin pump. we hypothesize that a bedtime snack is not necessary if the bedtime insulin is very well adjusted and delivered, especially by use of insulin pump which is considered the "gold standard" for overnight blood glucose control.

nocturnal hypoglycemia is a significant side effect of insulin replacement therapy and can lead to many problems including coma and death in the most extreme cases and deterioration of glycemic control. strategies to prevent nocturnal hypoglycemia include development of newer insulins and delivery systems and the use of specific bedtime snack compositions. detection of nocturnal hypoglycemia, as it occurs in everyday life, has been a problem since most episodes go unnoticed and therefore untreated leading to a very dangerous situation. with the recent availability of technology which allows for continuous glucose monitoring , it has been made possible to detect nocturnal hypoglycemia as it occurs in daily life. as well, this technology allows for the possibility of better titration of therapy. therefore, the goal of our study was to use continuous glucose monitoring technology as a tool to optimize titration of insulin therapy and as a means to detect nocturnal hypoglycemia as it occurs in daily life. specifically, we sought to compare the use of insulin pump therapy with no bedtime snacks and using a new type of insulin called an analogue(lispro) versus multiple daily injections of insulin, using the same type of insulin analogue, and with and without bedtime snacks. therefore, we compared 3 groups: 1) insulin pump with no bedtime snacks; 2) multiple injections with bedtime snacks and 3) multiple injections with no bedtime snacks. the groups were primarily compared for the occurrence and frequency of nocturnal hypoglycemia. other comparisons included: long term glycemic control (a1c), weight and body composition and quality of life.

Eligibility criteria:
inclusion criteria: * adults with type 1 diabetes for more than 3 years duration and on intensive insulin therapy using multiple daily injections of insulin (mdi) for at least 1 year prior to study. exclusion criteria: * pregnant women or intending to become pregnant in next year, * significant hepatic or renal disease, * active cancer, * abuse of alcohol or drugs.

Keywords: nocturnal hypoglycemia bedtime snacks continuous glucose monitoring continuous subcutaneous insulin infusion csii intensive therapy
deep brain stimulation for obsessive compulsive disorder (ocd pmcf)

Conditions: Obsessive Compulsive Disorder

Summary: the purpose of the study is to monitor the safety and performance of reclaim® deep brain stimulation (dbs) therapy in patients with chronic, severe, treatment-resistant obsessive compulsive disorder.

ocd is an anxiety disorder characterized by intrusive thoughts or images (obsessions), which increase anxiety, commonly accompanied by repetitive or ritualistic actions (compulsions), which decrease anxiety. the most frequent symptoms are contamination concerns with consequent washing or concerns about harm to self or others with consequent checking. although many ocd patients benefit from pharmacotherapy or cbt, between 7% and 10% of ocd patients fail to benefit from these standard treatments and may be considered treatment-resistant with a chronic deteriorating course. the most severely afflicted and disabled of these patients may be indicated for neurosurgical treatments, often considered as a therapy of last resort. neurosurgical procedures currently used in the treatment of severe, treatment-resistant ocd include anterior cingulotomy, subcaudate tractotomy, limbic leucotomy (which is a combination of the first two procedures) and anterior capsulotomy. the commonality between the different neurosurgical procedures is the irreversible lesioning of bilateral neuroanatomical structures and/or interconnecting pathways that are believed to be involved in the control of affect and limbic function. an alternative neurosurgical treatment option to the standard lesioning procedures is reclaim® deep brain stimulation (dbs) therapy for ocd, which received ce mark in july 2009.

Eligibility criteria:
inclusion criteria: * signing and dating of informed consent * male and female patients at least 18 years of age * diagnosis of obsessive compulsive disorder * meeting the definition of treatment resistance exclusion criteria: * axis-i disorder primary to ocd * contraindication to implantation * suicide risk * risk of non-compliance
sonography-guided resection of brain mass lesions

Conditions: Tumor, Brain; Arteriovenous Malformations; Cavernoma; Intracerebral Hematoma

Summary: objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port.

intraoperative sonography is usially used in neurooncology to detect brain tumors and exclude their remnants. a few studies describe it's usage while removing hematomas or vascular malformations. ultrasound is the only method allowing to observe brain tissue in real time. it is chip and doesn't violate surgical workflow. main disadvantages of sonography are lengthy learning curve and poorer image quality compared to magnetic resonance imaging. novel acoustic coupling fluid, contrast-enhanced ultrasound and elastography expanded it's effectiveness. meanwhile problems of locating of isoechogenic lesions with poor margins and elimination of artefacts are steel actual. objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port. a surgeon will intraoperatively locate mass lesion and assess extent of it's resection with sonography. ultrasound scanning will be performed through the same surgical approach or at a distance through enlarged craniotomy, periodically or permanently. to facilitate approach to subcortical and deep small mass lesions ultrasound-guided needle or ultrasound wire-guided port will be used.

Eligibility criteria:
inclusion criteria: * all intracranial tumors * cavernomas * arteriovenous malformations * spontaneous (non-traumatic) intracerebral hemorrhages * traumatic intracerebral hemorrhages * supratentorial localization * newly diagnosed * age 18-100 years * stable hemodynamics exclusion criteria: * rapid cerebral dislocation * previously performed brain radiotherapy

Keywords: intraoperative sonography intraoperative ultrasound brain tumor cavernoma arteriovenous malformation intracerebral hematoma